Cargando…
Messenger RNA vaccines against SARS-CoV-2
The first two vaccines proven to be effective for inhibiting COVID-19 illness were both mRNA, achieving 95% efficacy (and safety) among 74,000 participants (half receiving placebo) after intramuscular delivery of two shots, 3–4 weeks apart. To view this Bench to Bedside, open or download the PDF.
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Elsevier Inc.
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7805392/ https://www.ncbi.nlm.nih.gov/pubmed/33740443 http://dx.doi.org/10.1016/j.cell.2020.12.039 |
| _version_ | 1783636301498548224 |
|---|---|
| author | Topol, Eric J. |
| author_facet | Topol, Eric J. |
| author_sort | Topol, Eric J. |
| collection | PubMed |
| description | The first two vaccines proven to be effective for inhibiting COVID-19 illness were both mRNA, achieving 95% efficacy (and safety) among 74,000 participants (half receiving placebo) after intramuscular delivery of two shots, 3–4 weeks apart. To view this Bench to Bedside, open or download the PDF. |
| format | Online Article Text |
| id | pubmed-7805392 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2021 |
| publisher | Elsevier Inc. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-78053922021-01-14 Messenger RNA vaccines against SARS-CoV-2 Topol, Eric J. Cell Bench to Bedside The first two vaccines proven to be effective for inhibiting COVID-19 illness were both mRNA, achieving 95% efficacy (and safety) among 74,000 participants (half receiving placebo) after intramuscular delivery of two shots, 3–4 weeks apart. To view this Bench to Bedside, open or download the PDF. Elsevier Inc. 2021-03-18 2021-01-13 /pmc/articles/PMC7805392/ /pubmed/33740443 http://dx.doi.org/10.1016/j.cell.2020.12.039 Text en © 2020 Elsevier Inc. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
| spellingShingle | Bench to Bedside Topol, Eric J. Messenger RNA vaccines against SARS-CoV-2 |
| title | Messenger RNA vaccines against SARS-CoV-2 |
| title_full | Messenger RNA vaccines against SARS-CoV-2 |
| title_fullStr | Messenger RNA vaccines against SARS-CoV-2 |
| title_full_unstemmed | Messenger RNA vaccines against SARS-CoV-2 |
| title_short | Messenger RNA vaccines against SARS-CoV-2 |
| title_sort | messenger rna vaccines against sars-cov-2 |
| topic | Bench to Bedside |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7805392/ https://www.ncbi.nlm.nih.gov/pubmed/33740443 http://dx.doi.org/10.1016/j.cell.2020.12.039 |
| work_keys_str_mv | AT topolericj messengerrnavaccinesagainstsarscov2 |